Introduction
============

With the aging population continuing to grow, there has been a significant rise in the prevalence of Type 2 diabetes mellitus (T2DM). It has been observed in practically all regions of the world, with 415 million people suffering from diabetes worldwide ([@B1]). In recent decades, people with diabetes in China have increased on a yearly basis. In 2007, there were about 40 million diabetics in China, and it has been estimated that diabetics in China will reach approximately 42.3 million by 2030 ([@B2]--[@B4]). By that time, China will replace India as the country with the most diabetes patients worldwide.

Diabetes influences the function of multiple organs in the human body, including the heart, brain, kidney, peripheral nerves, eyes, and feet. Additionally, there can also be more than 100 kinds of complications involved with the disease, and it is currently known as the disease with the most complications ([@B5]). Throughout recent years, studies on the correlation between diabetes and osteoporosis have been widely recognized by scholars. Both osteoporosis and diabetes are metabolic diseases, and they have a complicated relationship with each other. It is well recognized that type 1 diabetes mellitus can decrease bone mineral density (BMD) and increase the risk of bone fracture ([@B6]), while the correlation between T2DM and osteoporosis remains unclear. Therefore, it is necessary for both physicians and patients to be aware of the prevalence rate of osteoporosis in T2DM patients and to learn the relevant characteristics in the diagnosed populations for the sake of early prevention. At present, no systematic review and meta-analysis regarding the prevalence rate of osteoporosis in T2DM patients in China has been conducted.

The objective of this review was to acquire reference values for the prevalence of osteoporosis in T2DM patients utilizing the meta-analysis method. We also described the characteristics of T2DM patients with osteoporosis based on a large sample size, which is intended to provide evidence for physicians as well as the health supervision department.

Methods
=======

Search Strategy
---------------

According to the PRISMA (2009) standard, we searched PubMed, Scopus, Web of science, Cochrane Library, CNKI, Wanfang data for relevant studies (updated until June 6, 2017). Subject retrieval words and keywords were as follows: type 2 diabetes mellitus, diabetes, T2DM, osteoporosis, prevalence, and epidemiological investigation. Literature languages are not limited.

Study Selection
---------------

Studies involved in this review met the following criteria: the participants were clinically diagnosed with T2DM in the Chinese Mainland; the study design was a cross-sectional study; the test equipment utilized was the BMD dual-energy X-ray absorptiometry and the parts that were tested consisted of the lumbar or the hip. Notably, the prevalence of osteoporosis in T2DM patients can be directly extracted from literature or indirectly calculated.

Data Collection and Assessment Processes
----------------------------------------

The retrieved studies were simultaneously and independently screened by two reviewers based on the previously formulated inclusion criteria. The extraction content mainly consisted of the first author, date of publication, diagnostic criteria, sample size, test instrument, test parts, and prevalence. When research reporting positive detection rate of osteoporosis in more than one part was observed, we chose the positive detection rate of the lumbar vertebra to be the standard. After disqualified and repetitive studies removing, the remaining studies were subjected to full-text reading and re-screening. If the information provided were unclear or disputable, the corresponding author of the study would be contacted for a thorough inquiry. Then, decisions of whether to keep the information or discard it would be made. Throughout the course of this process, all disagreements between reviewers were resolved through discussion.

Included studies were graded in 7 aspects according to the Combie evaluation tool which is as follows ([@B7]): the study design was scientific and rigorous; the data collection method was reasonable; the response rate of participants was reported; the total representativeness of samples were favorable; the research objective and methods were reasonable; the power of the test was reported; the statistical method was correct. "Yes", "no" and "have no idea" were respectively utilized to evaluate each item, which was successively given 1 point, 0 points, and 0.5 points. The total score was 7.0 points (6.0∼7.0 points, 4.0∼5.5 points, and 0∼4.0 points were considered to an A, B and C level of quality respectively).

Statistical Analysis
--------------------

The primary analysis in this review was the pooled prevalence of osteoporosis in T2DM patients. Heterogeneity was evaluated using the Cochran Q statistic (*P*\< 0.10 was considered to be statistically significant) and was quantified using the *I*^2^ index (where *I*^2^\> 30% indicated moderate heterogeneity; *I*^2^\> 50% substantial heterogeneity; and *I*^2^\> 75% considerable heterogeneity). If the *I*^2^ test indicated a value \> 50% which reflected significant heterogeneity, then a random-effect model was carried out. Conversely, a fixed-effect model was implemented. The subgroup analysis was conducted based on sex (male or female), average age (younger or older than 60 years old), region (south or north), economic level (developed or less developed) and date of publication (2001∼2009 or 2010∼2016). Besides, a meta-regression analysis was applied as a means to explore the source of heterogeneity among all the studies. Specifically, the concomitant variable includes the date of publication, the female proportion in subjects, region, sample size, economic level, and average age. Funnel plot with the proportion as the abscissa and the standard error as the ordinate was adopted to reflect the publication bias directly. Begg's test and Egger's test were both applied to create a qualitative judgment on publication bias. Additionally, the trim and filling method would be utilized to evaluate the stability of the obtained result if necessary. All the above analyses were conducted using the Stata 12.0 version, and all reported *P* values were two-sided with a statistical significance level of 0.05.

Results
=======

Literature Search and Characteristics
-------------------------------------

[Figure 1](#F1){ref-type="fig"} outlines the search strategy and the selection process. Of the 539 relevant studies initially identified, 383 duplicated records were removed, and 68 articles were subsequently excluded after reading titles and abstracts due to their irrelevant clinical question or incorrect publication type.
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After the full-text review of 70 studies, we further excluded 16 studies that did not meet the inclusion criteria. Finally, 54 studies with 13462 diabetic patients were included in the meta-analysis ([@B8]--[@B61]). The majority (79.6%) of the included articles scored greater than 4 points as assessed through the Combie evaluation tool, which indicated high and moderate quality literature. The main characteristics and details of each study are summarized in [Table 1](#T1){ref-type="table"}.

###### 

Characteristics of included studies

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------
  ***No.***   ***Area***     ***Measuring instrument type***   ***Measure parts***                ***Sample size***   ***M/F***   ***Age (yr)***    ***Quality***
  ----------- -------------- --------------------------------- ---------------------------------- ------------------- ----------- ----------------- ---------------
  ([@B1])     Hunan          USA Hologic-QDR-4500A             Lumbar, Left Hip                   1253                0/1253      59.8±8.61         A

  ([@B2])     Liaoning       USA GE Lunar-Prodigy              Lumbar, Femoral Neck               100                 18/32       45∼75             B

  ([@B3])     Jiangsu        France DMS CHALLENGER             Lumbar, Left Hip                   52                  24/28       62.05±7.25        B

  ([@B4])     Guang dong     NR                                Lumbar, Left Hip                   165                 85/80       60.91±8.91        B

  ([@B5])     Zhejiang       USA GE Lunar-Prodigy              Lumbar                             72                  33/39       55.9±3.3          B

  ([@B6])     Jiangxi        France MEDILINK-OSTEOCORE2        Lumbar, Femoral Neck               100                 52/48       63.9±6.5          B

  ([@B7])     Hebei          France MEDILINK-OSTEOCORE2        Lumbar, Hip                        105                 59/46       62±11             B

  ([@B8])     Hunan          USA Hologic-QDR-4500A             Lumbar, Hip                        168                 0/168       60.95±12.16       A

  ([@B9])     Shanghai       China DEXAUNT2000                 Lumbar, Hip                        70                  29/41       68.26±7.35        B

  ([@B10])    Zhejiang       France DMS CHALLENGER             Lumbar, Femoral Neck, Whole Body   100                 NR          NR                C

  ([@B11])    Sichuan        NR                                Lumbar, Hip                        230                 100/130     NR                C

  ([@B12])    Liaoning       Korea OsteoSys-Dexxum T           Lumbar, Femoral Neck               232                 64/168      66.1±9.2          B

  ([@B13])    Anhui          USA GE Lunar-Prodigy              Lumbar, Hip                        118                 42/76       51.6±12.5         C

  ([@B14])    Anhui          NR                                Hip                                162                 87/75       45∼73             C

  ([@B15])    Jiangxi        France DMS CHALLENGER             Lumbar, Left Hip                   204                 95/109      59.54±10.30       B

  ([@B16])    Sichuan        NR                                Lumbar, Hip                        223                 135/88      NR                C

  ([@B17])    Tianjin        USA NOLAND-XR-800                 Lumbar, Hip                        168                 80/88       55.6±11.3         B

  ([@B18])    Beijing        USA Hologic-QDR-4500A             Lumbar, Hip                        306                 154/152     69.2±6.8          C

  ([@B19])    Beijing        NR                                Lumbar, Hip                        200                 96/104      65.43±8.53        B

  ([@B20])    Guizhou        Janpan DAS 600EX                  Lumbar                             38                  38/0        74.0±6.9          C

  ([@B21])    [Hebei]{.ul}   USA Hologic-QDR-4500A             Lumbar, Hip                        158                 158/0       65.8±5.7          B

  ([@B22])    Beijing        USA GE Lunar-Prodigy              Lumbar, Hip                        102                 41/61       41.0∼94.4         A

  ([@B23])    Heilongjiang   USA GE Lunar-Prodigy              Lumbar, Hip                        194                 91/103      76.85±4.55        C

  ([@B24])    Jilin          USA GE Lunar-Prodigy              Lumbar, Hip                        68                  68/0        52.85±10.9        B

  ([@B25])    Yunnan         NR                                Lumbar                             137                 56/81       59.96±11.73       B

  ([@B26])    Sichuan        France MEDILINK-OSTEOCORE2        Lumbar, Left Hip                   96                  0/51        65.37±7.86        A

  ([@B27])    Fujian         USA GE Lunar-Prodigy              Lumbar, Hip                        182                 97/85       65.11±3.68        B

  ([@B28])    Fujian         USA GE Lunar-Prodigy              Lumbar, Hip                        85                  0/85        NR                C

  ([@B29])    Jiangsu        USA GE Lunar-DPX-IQ               Lumbar, Hip                        70                  70/0        78.5±16.7         B

  ([@B30])    [Hebei]{.ul}   France MEDILINK-OSTEOCORE3        Lumbar, Hip                        150                 0/150       62.5±13.6         B

  ([@B31])    Henan          USA Hologic-QDR-4500A             Lumbar, Left Hip                   355                 194/162     NR                C

  ([@B32])    Jiangsu        USA Hologic-EXPLORER              Lumbar, Hip                        529                 268/261     63.07±11.20       B

  ([@B33])    Anhui          USA GE Lunar-Prodigy              Lumbar, Left Hip                   254                 131/123     70.9±9.81         A

  ([@B34])    Tianjin        USA GE Lunar-Prodigy              Lumbar, Hip                        125                 125/0       55.8±11.4         A

  ([@B35])    Yunnan         USA GE Lunar-Prodigy              Lumbar, Hip                        1218                679/602     63.79±10.33       B

  ([@B36])    Hunan          USA Hologic-Delhpi A              Lumbar, Left Hip                   3110                0/3110      59.3±10.8         A

  ([@B37])    Guangdong      USA NORLAND XR-36                 Lumbar, Hip                        61                  25/36       41∼71             B

  ([@B38])    Hunan          USA Hologic-QDR-4500A             Lumbar, Hip                        214                 0/214       59±8              A

  ([@B39])    Henan          USA Hologic-QDR-4500W             Lumbar                             52                  21/31       69±7              C

  ([@B40])    Guangdong      USA GE Lunar-DPX-L                Lumbar, Left Hip                   537                 203/334     50∼79             B

  ([@B41])    Guangdong      USA GE Lunar-DPX-IQ               Lumbar, Hip                        103                 55/48       61±7              B

  ([@B42])    Shanghai       USA GE Lunar-Prodigy              Lumbar, Hip                        70                  29/41       68.16±7.35        A

  ([@B43])    [Hebei]{.ul}   USA GE Lunar-DPX-NT               Lumbar, Hip, Distal Radius         50                  0/50        60.02±4.13        B

  ([@B44])    [Hebei]{.ul}   France MEDILINK-OSTEOCORE3        Lumbar, Hip                        46                  17/29       60.58±9.18        B

  ([@B45])    Beijing        USA NORLAND XR-36                 Lumbar, Hip                        52                  52/0        66.0±9.8          B

  ([@B46])    Liaoning       France DMS lexxos                 Lumbar, Hip                        62                  0/62        50∼82             A

  ([@B47])    Chongqing      China DEXAUNT2000                 Lumbar, Hip                        78                  31/47       71.25±9.46        B

  ([@B48])    [Hebei]{.ul}   France MEDILINK-OSTEOCORE3        Lumbar, Hip                        150                 0/150       62.98±12.12       B

  ([@B49])    Anhui          USA GE Lunar-Prodigy              Lumbar, Left Hip                   302                 114/188     50∼70             B

  ([@B50])    Hunan          USA Hologic-QDR-4500A             Lumbar, Left Hip                   197                 0/166       48∼81             B

  ([@B51])    Beijing        USA GE Lunar-Prodigy              Lumbar, Hip, Whole Body            104                 67/37       59±12             A

  ([@B52])    [Hebei]{.ul}   France MEDILINK-OSTEOCORE3        Lumbar, Hip, Whole Body            68                  0/68        64.79±8.29        B

  ([@B53])    [Hebei]{.ul}   USA GE Lunar-Prodigy              Lumbar, Hip, Whole Body            106                 544/52      59.89±9.60        B

  ([@B54])    Hunan          USA Hologic-QDR-4500A             Lumbar, Hip                        248                 98/150      M: 59.86±11.38\   A
                                                                                                                                  F: 61.25±9.57     
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: M, Male; F, Female; NR, Not Reported

Pooled Prevalence Rates of Osteoporosis in Diabetic Patients
------------------------------------------------------------

### Overall

The pooled prevalence rate of osteoporosis in diabetic patients was 37.8% (95%CI: 33.5%, 42.1%, I^2^=96.8%, *P*\<0.001) ([Fig. 2](#F2){ref-type="fig"}). Subgroup analyses were applied based on sex, average age, region, economic level, and publication year in order to explore the source of heterogeneity.
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### Sex

Thirty-one studies and thirty-seven studies reported the prevalence rates of osteoporosis in male and female patients, respectively. The aggregated results indicated that the prevalence rates of osteoporosis in female and male were 44.8% (95%CI: 39.4, 50.2%) and 37.0% (95%CI: 27.5%, 49.8%) respectively ([Table 2](#T2){ref-type="table"}).

###### 

Prevalence of osteoporosis according to different items

  ***Category***     ***Subgroup***   ***NO. of studies***   ***N (T2DM)***   ***Events (OP)***    ***Prevalence, 95%CI (%)***   **P *(Q test)***   **I*^2^(%)***   ***Publication bias***   
  ------------------ ---------------- ---------------------- ---------------- -------------------- ----------------------------- ------------------ --------------- ------------------------ -------
  Sex                Male             31                     3078             716                  37.0 \[27.5,49.8\]            \<0.001            90.4            0.905                    0.711
  Female             37               8477                   2982             44.8 \[39.4,50.2\]   96.1                          0.143              0.001                                    
  Average age        \<60             12                     5679             1649                 26.5 \[20.8,32.1\]            \<0.001            94.2            0.373                    0.584
  ≧60                29               5267                   1738             40.1 \[33.3,46.9\]   96.9                          0.511              \<0.001                                  
  Area               Northern         21                     2901             1048                 38.2 \[31.2,45.1\]            \<0.001            94.3            0.147                    0.007
  Southern           33               10561                  3332             37.6 \[32.0,43.2\]   97.5                          0.369              0.008                                    
  Economic           Developed        21                     3371             1092                 32.7 \[26.2,39.1\]            \<0.001            94.6            0.147                    0.155
  Less developed     33               10091                  3288             41.0 \[35.2,46.8\]   97.5                          0.193              0.001                                    
  Publication year   2001∼2009        18                     2500             1006                 42.3 \[32.2,52.4\]            \<0.001            96.8            0.596                    0.553
  2010∼2016          36               10962                  3374             35.6 \[31.0,40.1\]   96.4                          0.145              0.002                                    

Abbreviations: T2DM, Type 2 Diabetes Mellitus; OP: Osteoporosis

### Age

Twelve studies reported that patients average ages were younger than 60 years old, and the other twenty-nine studies reported 60 years old or older. The aggregated results revealed that the prevalence rates of osteoporosis in younger patients and older patients were 26.5% (95%CI: \[20.8%, 32.1%\]) and 40.1% (95%CI: \[33.3%, 46.9%\]) ([Table 2](#T2){ref-type="table"}).

### Area

We geographically divided China into the southern and the northern regions with the Qinling Mountains-Huaihe River. Twenty-one studies and thirty-three studies were conducted in the southern and northern areas respectively. The aggregated results demonstrated that the prevalence rates of osteoporosis in patients living in the south (38.2%, 95%CI: \[31.2%--45.1%\]) and north (37.6%, 95%CI: \[32.0%--43.2%\]) reflected to be nearly the same ([Table 2](#T2){ref-type="table"}).

### Economic Level

According to the China's National Bureau of Statistics, developed regions with a GDP higher than 4 trillion were Beijing, Shanghai, Tianjin, Chongqing, Guangdong, Jiangsu, Shandong, Zhejiang, and Henan. Less developed regions with GDP lower than 4 trillion were Sichuan, Hubei, Hebei, Hunan, Fujian, Anhui, Liaoning, Shanxi, Inner Mongolia, Jiangxi, Guangxi, Heilongjiang, Jilin, Yunnan, Shanxi, Guizhou, Xinjiang, Gansu, Hainan, Ningxia, Qinghai, and Tibet. The pooled results illustrated that the prevalence rates of osteoporosis in patients living in the developed areas and less developed areas were 32.7% (95%CI:26.2%, 39.1%) and 41.0% (95%CI:35.2%, 46.8%) respectively ([Table 2](#T2){ref-type="table"}).

### Publication Year

Eighteen studies were published between the 2000 and 2009 period, and 36 studies were published between 2010 and 2016. The merged results demonstrated that the prevalence rates of osteoporosis in diabetic patients from 2010 to 2016 and from 2001 to 2009 were 35.6% (95%CI: \[31.0%, 40.1%\]) and 42.3% (95%CI: \[32.2%, 52.4%\]) respectively ([Table 2](#T2){ref-type="table"}).

### Regression Analysis and Publication Bias

Pre-specified meta-regression designated that publication year, areas, sample size, economic level, and quality scores did not affect the merged prevalence. However, sex (*P*=0.011) and average age (*P*=0.022) in participants remarkably influenced the overall outcome. Significant asymmetry existed in the funnel plot ([Fig. 3](#F3){ref-type="fig"}). The results of the Begg's test (*P* = 0.058) and the Egger's test (*P* \< 0.001) lacked consistency, which hinted that publication bias existed ([Table 3](#T3){ref-type="table"}). Therefore, we adopted the trim and fill method to examine the publication bias. The number of trimming and filling study was one after three times of iteration. The *P* value presented no reversal result before and after trimming and filling (*P*\<0.001 and *P*\<0.001) as it designated that the results were comparatively stable even though the publication bias existed.
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###### 

Results of Meta-regression for the prevalence of osteoporosis in type 2 diabetes mellitus

  ***Covariate***                               ***Meta-regression coefficient***   ***95 % Confidence interval***   **P *value***
  --------------------------------------------- ----------------------------------- -------------------------------- ---------------
  Year of publication                           −0.008                              −0.020 to 0.003                  0.164
  Female proportion (%)                         0.189                               0.045 to 0.333                   0.011
  Area (northern vs southern)                   −0.006                              −0.099 to 0.087                  0.899
  Sample size                                   −0.00006                            −0.0002 to 0.00003               0.185
  Economic level (developed vs not developed)   −0.082                              −0.173 to 0.008                  0.072
  Average age                                   0.010                               0.002 to 0.018                   0.022
  Quality score                                 −0.013                              −0.051 to 0.024                  0.482

Discussion
==========

In this systematic review, we estimated that in Chinese mainland, (a) the pooled prevalence rate of osteoporosis in diabetic patients is 37.8%, (b) old age and being of the female sex are both factors which correlate with a higher prevalence of osteoporosis and (c) economic level has a potential impact on the prevalence of osteoporosis in T2DM patients. To our knowledge, we are the first to systematically collect and analyze the studies utilizing DXA in T2DM patients.

According to the current results, the merged prevalence rate of osteoporosis in T2DM patients was much higher than the prevalence rate of primary osteoporosis in the Chinese Mainland reported by Chen ([@B62]). Notably, Chen has suggested that long-term high blood glucose might increase the risk for osteoporosis in diabetic patients largely. Additionally, some pathological mechanisms were related to this problem, such as deficiency or disorder of insulin, obesity, sexual hormone disturbance, and diabetic complications ([@B63]). In the early stage, Sosa and Wakasugi supposed that diabetes would not significantly impair bone metabolic status ([@B64], [@B65]). Recently, Athulya et al. also reported a negative difference in BMD between diabetic and non-diabetic subjects in India ([@B66]). Nevertheless, they noticed that the prevalence of osteoporosis was higher in the T2DM group than that in the control group.

Based on the results of the regression analysis, gender was a significant risk factor of osteoporosis in T2DM patients. We observed that the prevalence rate of osteoporosis in female T2DM patients (44.8%) was much higher than that in males (37.0%), and that they were higher than the results of primary osteoporosis reported by Chen respectively ([@B62]). Furthermore, age was another significant risk factor of osteoporosis in T2DM patients. The prevalence rate of osteoporosis (40.1%) in patients with an average age above 60 was higher than that in patients under 60 (26.5%). This result was consistent with the generally accepted concept that human bone mass would decline with age after reaching a peak.

In the subgroup analysis of the region, we did not detect an apparent difference between the prevalence rates of osteoporosis in T2DM patients residing in the southern and northern regions of China (37.6%, 38.2%). However, these two rates were higher than that of primary osteoporosis in the south and north China in Chen's study (south: 23.17%, north: 20.13%) ([@B62]). Climates and eating habits, which were regarded as the influential factors of primary osteoporosis, appeared to have little impact on the prevalence rate of osteoporosis in T2DM patients in the south and north of China ([@B67]--[@B70]). The subgroup analysis of the economic level manifested that the prevalence rate of osteoporosis (32.7%) in diabetic patients from developed areas was significantly lower than that in patients from less developed regions (41%). Due to the in-equal distribution of medical resources, diabetic patients from developed areas are prone to receive better medical care and afford long-term medical expenses, which overall contributes to a more stable condition of diabetes.

On the contrary, a shortage of medical resources and a lower income level may aggravate the condition of diabetes, causing a high prevalence rate of osteoporosis. Notably, economic growth may be one of the primary reasons for the decline in osteoporosis prevalence in T2DM patients after the 2010 period (35.6%) compared with that in patients from 2001 to 2009 (42.3%). Therefore, we inferred that economic development was beneficial in establishing a stable T2DM condition, which is also crucial in preventing diabetic complications such as osteoporosis ([@B71]).

Study Limitations
-----------------

There were some limitations to this review. Firstly, we included 54 studies, but the number of involved participants still proves to be insufficient. Secondly, all patient information was obtained from hospitals and more women than men were involved in this study, which possibly leads to a higher pooled prevalence rate. Thirdly, a majority of included studies lacked the diabetes course information. Consequently, we were unable to analyze the associations between the diabetes course and the prevalence of osteoporosis in the subgroup analyses.

Conclusion
==========

This review demonstrates that osteoporosis is common in T2DM patients. Old age and being of the female sex proved to reflect a higher osteoporosis prevalence. Notably, economic development may favorably decrease the prevalence of osteoporosis in diabetic patients. However, it is necessary to conduct further studies so as to incorporate previous results, into clinical prevention for osteoporosis in T2DM patients.
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